ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
115.63
-1.92 (-1.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close117.55
Open116.00
Bid95.55 x 200
Ask127.00 x 1000
Day's Range114.27 - 118.34
52 Week Range31.38 - 126.16
Volume1,220,434
Avg. Volume1,290,558
Market Cap10.61B
Beta3.46
PE Ratio (TTM)-22.57
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 days ago

    Alnylam to partner with Scangos-led biotech on infectious disease drugs

    Vir Biotechnology, a San Francisco-based startup led by former Biogen CEO George Scangos, said Wednesday that it will work with Alnylam Pharmaceuticals to develop infectious disease treatments using the Cambridge company’s experimental technology. Under the agreement, the companies will collaborate to develop one of Alnylam’s (ALNY) potential drugs for hepatitis B, plus up to four additional treatments for infectious diseases. Alnylam will be eligible to receive over $1 billion in payments if the drugs hit certain milestones.

  • Reuters2 days ago

    UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment

    Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease. The partnership with Vir includes development of drugs for four other infectious diseases using RNAi technology, which aims to silence targeted genes to curb the production of disease-causing proteins and have limited side-effects. Under the deal, the drug developer would receive an undisclosed upfront payment and more than $1 billion in potential milestone payments among other things.

  • Reuters2 days ago

    Alnylam, Vir partner on RNAi-based drugs for infectious diseases

    Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B. Alnylam said it would receive an upfront payment, comprising cash and Vir's shares under the deal terms, and would be eligible for more than $1 billion in potential milestone payments among other things. The company also said it would terminate development of its hepatitis B drug and would work on a new treatment along with Vir for the disease, apart from collaborating on therapies for four other infectious diseases.

  • MarketWatch2 days ago

    Alnylam's stock set to rally after exclusive license deal with Vir Biotechnology

    Alnylam Pharmaceuticals Inc. said Wednesday it has entered into an exclusive license agreement with privately-held Vir Biotechnology to develop and sell RNAi therapeutics for infectious diseases, including ...

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
    Motley Fool15 days ago

    Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September

    Positive results from an important phase 3 clinical trial fueled optimism about the biotech.

  • GuruFocus.com17 days ago

    Analysts Act on Health Care Stocks

    Leerink upgrades AbbVie to Outperform

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • Investopedia21 days ago

    Why Biotech and Tech Will Push Stocks Higher In 4Q

    The tech and biotech sectors have buoyed the broader market this year, and they're not letting up anytime soon.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit23 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • Barrons.com25 days ago

    Gene Therapy: A Big Week for Many Names

    It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT

    Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call

  • 3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
    Motley Fool27 days ago

    3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?

    Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week's biggest biotech winners.

  • The Wall Street Journal28 days ago

    [$$] Alnylam's New Medicine To Enter Pricing Debate

    Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.

  • Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
    Investor's Business Daily29 days ago

    Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance

    Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.

  • Barrons.com29 days ago

    Alnylam Pharmaceuticals: Bet or Fold?

    When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.

  • Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
    Zacks29 days ago

    Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

    Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

  • Company News For Sep 21, 2017
    Zacks29 days ago

    Company News For Sep 21, 2017

    Companies in the news are: BBBY,FDX,ALNY,GIS

  • Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : September 21, 2017
    Capital Cube29 days ago

    Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : September 21, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session
    Zacks29 days ago

    Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session

    Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.

  • MarketWatch29 days ago

    Alnylam shares surge 40% on drug results that may herald a new type of medicine

    Many companies backed away from the gene silencing technique when big investments in the field didn’t pan out — but not Alnylam.

  • Alnylam Pharmaceuticals Shows Market Leadership With Jump To 98 RS Rating
    Investor's Business Daily29 days ago

    Alnylam Pharmaceuticals Shows Market Leadership With Jump To 98 RS Rating

    Alnylam Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

  • Morningstar29 days ago

    Boosting Fair Value on Alnylam After Drug Trial

    Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 ...

  • What Happened in the Stock Market Today
    Motley Foollast month

    What Happened in the Stock Market Today

    On a day stocks gyrated in response to Federal Reserve announcements, Bed Bath & Beyond fell sharply on earnings, and Alnylam Pharmaceuticals soared on a successful drug trial.

  • Alnylam Pharmaceuticals CEO: Trial results open up the do...
    CNBC Videos29 days ago

    Alnylam Pharmaceuticals CEO: Trial results open up the do...

    Alnylam Pharmaceuticals CEO John Maraganore discusses his company's successful drug trial to treat a rare nerve disorder, and what he sees for the underlying technology. With CNBC's Meg Tirrell.